Split History
LJPC split history picture
La Jolla Pharmaceutical (LJPC) has 1 split in our LJPC split history database. The split for LJPC took place on December 22, 2005. This was a 1 for 5 reverse split, meaning for each 5 shares of LJPC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.

When a company such as La Jolla Pharmaceutical conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the LJPC split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into La Jolla Pharmaceutical shares, starting with a $10,000 purchase of LJPC, presented on a split-history-adjusted basis factoring in the complete LJPC split history. LJPC split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 07/15/2010
End date: 07/14/2020
Start price/share: $0.04
End price/share: $4.27
Dividends collected/share: $0.00
Total return: 10,575.00%
Average Annual Total Return: 59.49%
Starting investment: $10,000.00
Ending investment: $1,067,690.67
Years: 10.01
La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for patients suffering from life-threatening diseases. GIAPREZATM (angiotensin II) is approved by the United States Food and Drug Administration as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. LJPC-0118 is Co.'s investigational product for the treatment of severe malaria. LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product, is being developed for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia and polycythemia vera. According to our LJPC split history records, La Jolla Pharmaceutical has had 1 split.
Date Ratio
12/22/20051 for 5
LJPC is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

LLY Split History
LPTN Split History
LUX Split History
LXRX Split History
MACK Split History
MBOT Split History
MBVX Split History
MCK Split History
MD Split History
MDCI Split History

Also explore: LJPC shares outstanding history

Altus Midstream Company (ATLM)
FS KKR Capital Corp. (FSK)
Groupon (GRPN)
XpresSpa Group, Inc. (XSPA)
Energy Focus, Inc. (EFOI)
The Cushing NextGen Infrastructure Income Fund (SZC)
Teligent, Inc. (TLGT)
Laredo Petroleum, Inc. (LPI)
Global Eagle Entertainment Inc. (ENT)
ToughBuilt Industries, Inc. (TBLT)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

LJPC Insider Buying

LJPC Split History | www.SplitHistory.com | Copyright © 2013 - 2020, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.